Chemometec A/ (CHEMM.CO) traded up 2.87 % during a 24 hours period ending at 10:13 PM Central Europe on Tuesday 27th. One Chemometec A/ stock can currently be bought for about DKK 608 on popular exchanges. Current supply of Chemometec A/ stocks is 17.2 mn. Chemometec A/ has a current market capitalization of DKK 10.5 bn and approximately DKK 25.1 mn worth of Chemometec A/ was traded on exchanges in the last 24 hours. Since last month end, Chemometec A/ has traded 16.65 % up. Simple moving average of last 200 days is at DKK 443.1. The highest price of past 52 weeks was recorded at DKK 804 on 10/30/2025. 52 weeks low was at DKK 235.2 on 03/24/2026.
Summary of the latest news for Chemometec A/
CHEMOMETEC A/S is among the Danish companies that have attracted notable short‑selling activity, according to recent aggregated net‑short position reports from the Danish financial supervisory authority. The firm’s net short exposure stands at just above three percent of its share capital, placing it in the upper tier of companies with significant short interest. This level of coverage suggests that a portion of market participants hold bearish views on the company’s near‑term performance. No further details on the drivers behind the short positions are disclosed in the reports. The information indicates a measurable level of skepticism among investors, which could influence market sentiment around CHEMOMETEC A/S in forthcoming trading sessions.
Here is how related stocks have performed in the past 24 hours:
Scandinavian Tobacco (STG.CO) traded down -0.13 % and now trades at DKK 76.5. Scandinavian Tobacco has a market capitalisation of DKK 6.1 bn. Current price/earnings ratio for Scandinavian Tobacco is 9.38. Scandinavian Tobacco Group AS is preparing to release its latest quarterly results in early November, following a forecast that suggests a modest improvement in earnings and revenue compared with the same period last year. Market data shows that the company’s shares have attracted a small short‑position relative to other Danish firms, indicating limited bearish sentiment among investors. Analysts expect the forthcoming figures to confirm a slight rise in profitability and sales, which could support the stock’s recent stability in the market. The company’s upcoming conference call is anticipated to provide further detail on performance drivers and outlook for the remaining fiscal year. No additional corporate actions or significant market movements have been reported in connection with the group at this time.
D/s Norden (DNORD.CO) traded up 5.97 % and now trades at DKK 382.8. D/s Norden has a market capitalisation of DKK 10.6 bn. D/s Norden has a current price to earnings ratio of 11.09. On Thursday, the Danish shipping company D/S Norden released its quarterly results amid a busy week of corporate disclosures. Analysts noted that the company’s performance was broadly in line with expectations, reflecting stable operational conditions in the Baltic trade environment. While the announcement did not signal any dramatic shifts in earnings or guidance, it reinforced the broader market narrative that shipping operators are maintaining resilience amid fluctuating freight rates and geopolitical tensions. Investors observing the sector highlighted that D/S Norden’s update, together with other Danish firms such as Tivoli and Netcompany, contributes to a nuanced view of Denmark’s corporate landscape during the earnings cycle. The company’s report is likely to be factored into market assessments as the week progresses and further financial data is released.
Embla Medical Hf (EMBLA.CO) traded up 2.26 % and now trades at DKK 26.75. Current market capitalisation for Embla Medical Hf is DKK 11.6 bn. Current price/earnings ratio for Embla Medical Hf is 18.55. Embla Medical hf. has reported that it completed a tranche of share repurchases under its ongoing buy‑back programme. Between 19 and 23 October, the company purchased roughly fifty‑one thousand shares, bringing the total number of outstanding shares to about 2.88 million, or just under one percent of the company’s equity. The transaction, which followed an earlier announcement in July, is part of Embla’s broader strategy to manage its capital structure and support shareholder value.
Dfds A/ (DFDS.CO) traded up 4.18 % and now trades at DKK 166.8. Dfds A/ has a market capitalisation of DKK 8.6 bn. Danske Bank has raised its target price for DFDS A/S, citing a favourable spread on bunker fuel that is expected to support earnings through 2027. The bank maintains a neutral “hold” recommendation, noting uncertainty around the company’s Southern European operations and the potential for write‑downs amid a strategic review. DFDS’ share price closed higher on the day, reflecting the upward revision. In market‑wide short‑position data, DFDS appears among a small group of Danish companies with short exposure, although its position is modest compared with peers. No further corporate actions or earnings guidance are reported at this time.
Sjf Bank A/ (SJF.CO) traded up 2.26 % and now trades at DKK 482. Current market capitalisation for Sjf Bank A/ is DKK 7.7 bn. Current price/earnings ratio for Sjf Bank A/ is 13.74. SJF Bank A/S announced the commencement of a share‑repurchase programme in June, aimed at reducing its share capital under EU safe‑harbour regulations. During the week of 19‑23 October 2026, the bank executed a series of buy‑backs amounting to several hundred thousand shares, with average purchase prices ranging from mid‑four‑hundred to near five‑hundred Danish kroner per share. The transactions were carried out by Danske Bank on the bank’s behalf, and the programme is scheduled to conclude by February 2027. Following these purchases, SJF Bank now holds roughly one‑and‑a‑quarter percent of its own capital, after accounting for shares related to employee‑ownership plans. The programme is documented in the company’s public disclosure and complies with the relevant European Commission directives.
About Chemometec A/
Chemometec A/S is a health care company operating in the life sciences tools and services sector. Established in 1997, it has its main operations at its headquarters located in Allerod, Denmark. The company specializes in designing, developing, and producing instruments for various applications in cell counting and evaluation. These include automated cell counters and viability analyzers such as NucleoCounter NC-3000, an advanced image cytometer to characterize cell properties; NucleoCounter NC-250, an automated cell analyzer to characterize cell properties; NucleoCounter NC-200, an automated cell counter that provides solutions for cell counting and cell viability determinations; NucleoCounter NC-100, a mammalian cell counter; NucleoCounter SP-100, a sperm cell counter that offers total sperm concentration and sperm viability in a semen sample from ejaculates or extended doses; NucleoCounter YC-100, a yeast cell counter used to measure the total cell count and viability of yeast cells in suspension; NucleoCounter SCC-100, a somatic cell counter for measuring the amount of somatic cells in a milk sample; and NucleoCounter SCC-400, a somatic cell counter for determining the number of somatic cells in a milk sample. Additionally, the company offers Xcyto, a quantitative cell imager to analyze adherent and suspension cells; NucleoView, a software that serves as the user interface for the NucleoCounter NC-200, NC-250, and NC-3000 instruments, handling data acquisition, image analysis, and data presentation; consumables including cassettes, reagents, slides, and test kits; and accessories including cables, power supplies, software, and other products. ChemoMetec A/S’s solutions are applied in various areas such as cell therapeutic, stem cell research, cancer cell research, bioprocessing, toxicology, cell biology research, sperm cell counting, yeast cell counting, and somatic cell counting.